Video
About 50% of patients with congestive heart failure (CHF) have preserved ejection fraction.
CHF with preserved ejection fraction has had no effective therapy other than to have good control of CVD risk factors (BP, lipids and smoking). The SGLT2 inhibitors are the first treatment to improve outcomes and so are a game changer when it comes to treating this condition.
Dr Devlin will walk us through the issues of treatment with SGLT2 inhibitors and ways to make the cost cheaper for patients as they are currently unfunded for CHF (only diabetes).
As always, we will answer as many questions as possible during this session.
Presenter
Gerry Devlin
MB BCh BAO BA MD FRACP FCSANZ FESC
Gerry is the current Medical Director of the Heart Foundation and a cardiologist at Te Whatu Ora Tairáwhiti. He is an Honorary Associate Professor with the University of Auckland. Gerry is an experienced general cardiologist, with a special interest in the prevention and management of coronary artery disease, hypertension and heart failure.
Gerry is a graduate of Trinity College Dublin Ireland and moved to New Zealand in 1988. Gerry is a busy clinical researcher with over 120 publications. Research interests include acute coronary syndromes, heart failure and systems of care.
Supported by an unrestricted educational grant from:
